Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anjana Anilkumar Sithara

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
NAR Genomics and Bioinformatics|July 28, 2022
iCOMIC: a graphical interface-driven bioinformatics pipeline for analyzing cancer omics dataAnjana Anilkumar Sithara, Devi Priyanka Maripuri, Keerthika Moorthy, et al.
Journal of Leukocyte Biology|August 27, 2024
Deubiquitinase BAP1 is crucial for surface expression of T cell receptor (TCR) complex, T cell-B cell conjugate formation, and T cell activationDhwani Radhakrishnan, Jana Kotulová, Lucie Hofmanová, et al.
International Journal of Molecular Sciences|March 29, 2023
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB SignalingMarcello Turi, Anjana Anilkumar Sithara, Lucie Hofmanová, et al.
Blood Cancer Journal|February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeuticsDaisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.
British Journal of Haematology|October 9, 2023
Insight into the mechanism of CD34<sup>+</sup> cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapyOndrej Venglar, Veronika Kapustova, Anjana Anilkumar Sithara, et al.
Blood Advances|September 9, 2021
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicineMartina Zátopková, Tereza Ševčíková, Viola Fanfani, et al.
Blood|August 22, 2024
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myelomaMara John, Moutaz Helal, Johannes Duell, et al.
Blood Cancer Discovery|November 14, 2025
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentAnjana Anilkumar Sithara, Veronika Kapustova, David Zihala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Blood|December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbsTomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
NAR Genomics and Bioinformatics|July 28, 2022
iCOMIC: a graphical interface-driven bioinformatics pipeline for analyzing cancer omics dataAnjana Anilkumar Sithara, Devi Priyanka Maripuri, Keerthika Moorthy, et al.
Journal of Leukocyte Biology|August 27, 2024
Deubiquitinase BAP1 is crucial for surface expression of T cell receptor (TCR) complex, T cell-B cell conjugate formation, and T cell activationDhwani Radhakrishnan, Jana Kotulová, Lucie Hofmanová, et al.
International Journal of Molecular Sciences|March 29, 2023
Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB SignalingMarcello Turi, Anjana Anilkumar Sithara, Lucie Hofmanová, et al.
Blood Cancer Journal|February 3, 2023
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeuticsDaisuke Ogiya, Zuzana Chyra, Sigitas J Verselis, et al.
British Journal of Haematology|October 9, 2023
Insight into the mechanism of CD34<sup>+</sup> cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapyOndrej Venglar, Veronika Kapustova, Anjana Anilkumar Sithara, et al.
Blood Advances|September 9, 2021
Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicineMartina Zátopková, Tereza Ševčíková, Viola Fanfani, et al.
Blood|August 22, 2024
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myelomaMara John, Moutaz Helal, Johannes Duell, et al.
Blood Cancer Discovery|November 14, 2025
Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironmentAnjana Anilkumar Sithara, Veronika Kapustova, David Zihala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Blood|December 17, 2025
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbsTomas Jelinek, David Žihala, Aintzane Zabaleta, et al.
Pageof 1